Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04174196 · ClinicalTrials.gov registry record · Phase 2

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

A Phase 2 study of Multiple Myeloma and Plasmacytoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
21
Enrollment target
7
Study locations

NCT04174196 is a Phase 2 study of Multiple Myeloma and Plasmacytoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04174196, a Phase 2 study of Multiple Myeloma and Plasmacytoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
21 participants
Enrollment target
7
Study locations

Study Summary

The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

Conditions Studied

Multiple Myeloma Plasmacytoma Plasmacytoma of Bone

Interventions

  • RADIATION Radiation Therapy
  • DRUG Lenalidomide
  • DRUG CC-486

Study Locations (7)

New York

  • Memorial Sloan Kettering Cancer Center @ Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2019-11-19
Est. Completion 2026-11-19
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04174196

The ClinicalTrials.gov registry entry for NCT04174196 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.

NCT04174196 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.

Frequently Asked Questions

What is clinical trial NCT04174196 about?

NCT04174196 is a clinical study titled "A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma". The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

What is the current status of trial NCT04174196?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2019-11-19. Estimated completion is 2026-11-19.

What conditions does trial NCT04174196 study?

This clinical trial studies the following conditions: Multiple Myeloma, Plasmacytoma, Plasmacytoma of Bone.

What interventions are being tested in trial NCT04174196?

The interventions under investigation include: Radiation Therapy (RADIATION), Lenalidomide (DRUG), CC-486 (DRUG).

Who is sponsoring clinical trial NCT04174196?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04174196 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Plasmacytoma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.